This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colevas, A. D. Search for Related Content PubMed PubMed Citation Articles by Colevas, A. D. Social Bookmarking                            What's this?

Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

A. Dimitrios Colevas

From the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD

Address reprint requests to Executive Plaza N, Room 7131, 6130 Executive Blvd, Rockville, MD 20852; e-mail: colevasd{at}ctep.nci.nih.gov

The purpose of this review is to provide readers with guidance concerning treatment of patients with advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in the context of clinical trial data. We discuss issues surrounding the treatment of patients with SCCHN, with an emphasis on recommendations based on results from phase II and III clinical trials published since 1980. Many options exist for the treatment of patients with SCCHN. The most important decisions involve determining which patients are in need of treatment and which are most likely to benefit from treatment. Although many chemotherapy treatments have been shown to induce responses, survival improvement remains an unfulfilled goal. Definitive data do not exist on the effects of chemotherapy on quality of life or progression-free survival as measures of clinical benefit in this setting. Performance status, history of prior treatment, extent of tumor, and need for palliation are the most important factors in the decision to treat a patient with chemotherapy for incurable SCCHN. Single-agent treatment with conventional doses of methotrexate remains a standard for most patients with advanced, recurrent or metastatic SCCHN. Cisplatin plus fluorouracil, cisplatin plus a taxane, and single-agent taxane are the most widely studied alternatives. There is a need for further trials with end points other than overall survival or tumor response in this patient population. Guidelines for patient selection and treatment options are provided.

Author's disclosures of potential conflicts of interest is found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. Nakajima, A. Matsunaga, D. Ichimaru, Y. Urata, T. Fujiwara, and K. Kawakami Telomerase-specific virotherapy in an animal model of human head and neck cancer Mol. Cancer Ther., January 1, 2009; 8(1): 171 - 177. [Abstract] [Full Text] [PDF]

				T.-F. Wang, S.-C. Chu, R.-H. Kao, C.-Y. Yao, and C.-C. Li A Phase II Study of Weekly Paclitaxel and Epirubicin in Recurrent or Refractory Squamous Cell Carcinoma of the Head and Neck Jpn. J. Clin. Oncol., July 1, 2008; 38(7): 459 - 463. [Abstract] [Full Text] [PDF]

				M. Tran, P. Rousselle, P. Nokelainen, S. Tallapragada, N. T. Nguyen, E. F. Fincher, and M. P. Marinkovich Targeting a Tumor-Specific Laminin Domain Critical for Human Carcinogenesis Cancer Res., April 15, 2008; 68(8): 2885 - 2894. [Abstract] [Full Text] [PDF]

				S. Marur and A. A. Forastiere Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment Mayo Clin. Proc., April 1, 2008; 83(4): 489 - 501. [Abstract] [Full Text] [PDF]

				N. Choong and E. Vokes Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53. [Abstract] [Full Text] [PDF]

				T. M. Pawlik, A. L. Gleisner, T. W. Bauer, R. B. Adams, S. K. Reddy, B. M. Clary, R. C. Martin, C. R. Scoggins, K. K. Tanabe, J. S. Michaelson, et al. Liver-Directed Surgery for Metastatic Squamous Cell Carcinoma to the Liver: Results of a Multi-Center Analysis Ann. Surg. Oncol., October 1, 2007; 14(10): 2807 - 2816. [Abstract] [Full Text] [PDF]

				C. Elser, L. L. Siu, E. Winquist, M. Agulnik, G. R. Pond, S. F. Chin, P. Francis, R. Cheiken, J. Elting, A. McNabola, et al. Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma J. Clin. Oncol., August 20, 2007; 25(24): 3766 - 3773. [Abstract] [Full Text] [PDF]

				A. A. Forastiere, A. Trotti, D. G. Pfister, and J. R. Grandis Head and Neck Cancer: Recent Advances and New Standards of Care J. Clin. Oncol., June 10, 2006; 24(17): 2603 - 2605. [Full Text] [PDF]